RVV.C

Revive Therapeutics Ltd.

UPDATE — Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamineโ€™s profile as b... Read More...

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Novel discovery and research originated from Universidad Central del Caribe and St. Jude Childrenโ€™s Research HospitalMedicinal mushroom compound with anticancer activities that have minimal effects on normal cellsShowed superior potency against aggressive breast cancer with potential to treat aggressive malignancies such as triple negativ... Read More...

Revive Therapeutics Approved to Trade on the OTCQB Market

TORONTO, June 25, 2021 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that its common shares have been approved for trading on the OTCQBยฎ Ma... Read More...

Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Sept. 29, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Companyโ€™s U.S. Food & Drug Administration (โ€œU.S. FDAโ€) Phase 3 c... Read More...

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

TORONTO, Sept. 02, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company has entered into a Clinical Trial Agreement (CTA), dated August 28, ... Read More...

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

TORONTO, Aug. 11, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce, further to its press release of June 12, 2020, that under its sponsored research partn... Read More...

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

TORONTO, April 03, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€) (CSE:RVV), a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, announced today that it has filed its Pre-Investigational New Drug (โ€œpre-INDโ€) meeting request with the U.S. Food and Drug Ad... Read More...

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

TORONTO, March 20, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€) (CSE:RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (COVID-19). The Company has applied for a pro... Read More...

Revive Therapeutics Announces Closing of Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, March 18, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€) (CSE:RVV), a cannabis and psychedelic life sciences company, is pleased to announce that further to its ... Read More...

Revive Therapeutics Announces Brokered Private Placement of up to $2 million

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, Feb. 11, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€ or the โ€œCompanyโ€), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory dis... Read More...

Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units

TORONTO, Feb. 05, 2020 -- Revive Therapeutics Ltd. (โ€œReviveโ€), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units (the โ€œDebenture Unitsโ€) to armโ€™s length parties for aggregate gross proceeds of ... Read More...